Prevalence and prognostic significance of neuroendocrine differentiation in colorectal carcinomas

Endocrine Pathology

Volumn 9, Issue 1, 1998, Pages 35-42

  Lloyd, Ricardo V ^a   Schroeder, Georgene ^a   Bauman, Mitchel D ^b   Krook, James E ^c   Jin, Long ^a   Goldberg, Richard M ^a   Farr Jr , Gist H ^d  

^a MAYO CLINIC   (United States)

^b Siouxland Hematology Oncology Associates   (United States)

^c Duluth Community Clinical Oncology Program   (United States)

^d Ochsner CCOP   (United States)

Author keywords

Chromogranin; Colorectal carcinoma; In situ hybridization; Neuroendocrine cells

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B;

ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031777489     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02739950     Document Type: Article

References (31)

1. Kubo T, Watanabe H. Neoplastic argentaffin cells in gastric and intestinal carcinomas. Cancer 27:447-454, 1971.
2. Iwashita A. Argyrophil and argentaffin cells in carcinomas of the colon and rectum. Fukuoka Acta Med 70:370-390, 1979.
3. Smith DM, Haggitt RC. The prevalence and prognostic significance of argyrophil cells in colorectal carcinomas. Am J Surg Pathol 8:123-128, 1984.
4. Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, et al. Endocrine cells and prognosis in patients with colon carcinoma. Cancer 69:2641-2646, 1992.
5. Park J-G, Choe GY, Helman LJ, Gazdar AF, Yang H-K, Kim J-P, et al. Chromogranin A expression in gastric and colon cancer tissues. Int J Cancer 51:189-194, 1992.
6. De Bruine AP, Wiggers TH, Beek C, Volovics A, Von Meyenfeldt M, Arends JW, et al. Endocrine cells in colon adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 54:765-771, 1993.
7. Syversen V, Halvorsen T, Mårvik R, Waldum HL. Neuroendocrine differentiation in colorectal carcinomas. Eur J Gastroenterol Hepatol 7:667-674, 1995.
8. Lapertosa G, Baracchini P, Delucchi F. Prevalence and prognostic significance of endocrine cells in colorectal adenocarcinomas. Pathologica 86:170-173, 1994.
9. Mori M, Mimori K, Kamakura T, Adachi Y, Ikeda Y, Sugimachi K. Chromogranin positive cells in colorectal carcinoma and transitional mucosa. J Clin Pathol 48:754-758, 1995.
10. Facer P, Bishop AE, Lloyd RV, Wilson BS, Hennessy RJ, Polak JM. Chromogranin: a newly recognized marker for endocrine cells of the human gastrointestinal tract. Gastroenterology 89:1366-1373, 1985.
11. Lloyd RV, Wilson BS. Specific endocrine tissue marker defined by a monoclonal antibody. Science 222:628-630, 1983.
12. Lloyd RV, Jin L, Kulig E, Fields K. Molecular approaches for the analysis of chromogranins and secretogranins. Diagn Mol Pathol 1:2-15, 1992.
13. Pagani A, Papotti M, Abbona GC, Bussolati G. Chromogranin gene expression in colorectal adenocarcinomas. Mod Pathol 8:626-632, 1995.
14. Simon SR, Fox K. NE carcinoma of the colon. J Clin Gastroenterol 17:304-307, 1993.
15. Wick MR, Weatherby RP, Weiland LH. Small cell neuroendocrine carcinoma of the colon and rectum: clinical, histologic and ultrastructural study and immunohistochemical comparison with cloacogenic carcinoma. Hum Pathol 18:9-21, 1987.
16. Gaffey MJ, Mills SG, Lack EE. Neuroendocrine carcinoma of the colon and rectum. A clinicoparhologic, ultrastrucrural and immunohistochemical study of 24 cases. Am J Surg Pathol 14:1010-1023, 1996.
17. Lloyd RV, Jin L. In situ hybridization analysis of chromogranin A and B mRNAs in neuroendocrine tumors with digoxigenin-labeled oligonucleotide probe cocktails. Diag Mol Pathol 4:143-151, 1995.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
19. Fischer-Colbrie R, Hagn C, Schober M. Chromogranins A, B and C: widespread constituents of secretory vesicles. Ann NY Acad Sci 493:120-134, 1987.
20. Huttner WB, Gerdes H-H, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 16:27-30, 1991.
21. Jin L, Chandler WF, Smart JB, England BG, Lloyd RV. Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression. J Clin Endocrinol Metab 76:728-735, 1993.
22. DeLellis RA, Tischler AS, Wolfe HJ. Multidirectional differentiation in neuroendocrine neoplasia. J Histochem Cytochem 32:899-904, 1984.
23. Abrahamsson PA, Falkmer S, Fait K, Grimelius L. The course of NE differentiation in prostatic carcinomas. An immunohistochemical study resting chromogranin A as an "endocrinc marker." Path Res Pract 185:373-380, 1989.
24. Linnoila RI, Mulshine JL, Steinberg SM, Funa K, Matthews MJ, Cotelingam JD, et al. NE differentiation in endocrine and non-endocrine lung carcinomas. Am J Clin Pathol 90:641-652, 1988.
25. Erikstein B, Nesland JM, Ottestad E, Lund E, Johannessen JV. Neuron specific enolasepositive breast carcinomas. Histol Histopathol 3:97-102, 1988.
26. Pagani A, Papotti M, Höfler H, Weiler R, Winkler H, Bussolati C. Chromogranin A and B gene expression in carcinomas of the breast. Am J Pathol 136:319-327, 1990.
27. Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK, et al. Are diffuse gastric carcinomas neuroendocrine tumours (ECL-omas)? Eur J Gastroenrerol Hepatol 32:245-249, 1991.
28. Matsui K, Kitagawa M, Miwa A, Kuroda Y, Tsuji M. Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases. Am J Gastroenterol 86:1167-1175, 1991.
29. Park JG, Choe GY, Helman LJ, Gadzar AF, Yang HK, Kim JP, et al. Chromogranin A expression in gastric and colon cancer tissue. Int J Cancer 51:189-194, 1992.
30. Saclarides TJ, Szeluga D, Staren ED. Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience. Dis Colon Rectum 37:635-642, 1994.
31. Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB. Goblet cell carcinoids and related tumors of the vermiform appendix. Am J Clin Pathol 94:27-35, 1990.